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Abstract
Background: It is uncertain if whole-pelvic irradiation (WPRT) in addition to dose-escalated prostate bed irradiation
(PBRT) improves biochemical progression-free survival (bPFS) after prostatectomy for locally advanced tumors. This
study was initiated to analyze if WPRT is associated with bPFS in a patient cohort with dose-escalated (> 70 Gy)
PBRT.
Methods: Patients with locally advanced, node-negative prostate carcinoma who had PBRT with or without WPRT
after prostatectomy between 2009 and 2017 were retrospectively analyzed. A simultaneous integrated boost with
equivalent-doses-in-2-Gy-fractions (EQD-2) of 79.29 Gy or 71.43 Gy to the prostate bed was applied in patients with
margin-positive (or detectable) and margin-negative/undetectable tumors, respectively. WPRT (44 Gy) was offered to
patients at an increased risk of lymph node metastases.
Results: Forty-three patients with PBRT/WPRT and 77 with PBRT-only were identified. Baseline imbalances included
shorter surgery-radiotherapy intervals (S-RT-Intervals) and fewer resected lymph nodes in the WPRT group. WPRT
was significantly associated with better bPFS in univariate (p = 0.032) and multivariate models (HR = 0.484, p =
0.015). Subgroup analysis indicated a benefit of WPRT (p = 0.029) in patients treated with rising PSA values who
mostly had negative margins (74.1%); WPRT was not associated with a longer bPFS in the postoperative setting
with almost exclusively positive margins (96.8%).
Conclusion: We observed a longer bPFS after WPRT compared to PBRT in patients with locally advanced prostate
carcinoma who underwent dose-escalated radiotherapy. In subset analyses, the association was only observed in
patients with rising PSA values but not in patients with non-salvage postoperative radiotherapy for positive
margins.
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Background
Post-prostatectomy radiotherapy can be given as adjuvant
[1–3] or salvage [4] treatment with or without androgen-
deprivation therapy (ADT) [5, 6]. The addition of ADT
has just recently been shown to improve biochemical
progression-free survival (bPFS) [5] and also overall sur-
vival (OS) after longer follow-up [6] when added to
moderate-dose radiation therapy (66 and 64.8 Gy, respect-
ively, at the lower end of most recent EU and US guideline
recommendations (≥66 and ≥ 64–65Gy [7, 8])). Although
an optimal dose has not been established for salvage or
adjuvant radiotherapy, some series indicate that doses >
70Gy might improve bPFS [7–12]; however, dose escal-
ation was associated with increased risk of toxicity even in
recent series using highly conformal techniques such as
intensity-modulated radiotherapy (IMRT) [13–15].
Aside from dose escalation and addition of ADT, there
is ongoing discussion about the effect of elective whole-
pelvic radiotherapy (WPRT). Despite negative studies in
the primary setting [16, 17] and an absence of evidence
in the post-prostatectomy situation at the time when the
survey was conducted, WPRT has been considered by
74% of radiation oncologists in the salvage setting [18].
Interim results from the 3-arm randomized NRG-
Oncology/RTOG-0534 trial support this approach; the
study recently reported a bPFS benefit in the salvage set-
ting by adding ADT or ADT plus WPRT to prostate bed
(“fossa-only”; PBRT) irradiation [19].
We primarily conducted this study to analyze out-
comes of patients with locally advanced but lymph-
node-negative tumors (T3–4/N0) treated with two
standardized, dose-escalated (71.43–79.29 Gy equivalent-
doses-in-2-Gy-fractions, EQD-2) post-prostatectomy
radiotherapy strategies with or without WPRT (44 Gy,
EQD-2 with volumes in line with RTOG recommenda-
tions [20]). Supplementary analyses were done as a
pooled cohort with all node-negative patients (including
T1–2/N0) and with node-positive patients (N1); how-
ever, both groups were not included in the main model
due to extreme imbalances of PBRT and WPRT usage.
Methods
Patients
Following institutional review board approval (2018-509
N-MA), we analyzed charts of 244 patients that were
treated between 01/2009 and 07/2017 (≥6 months
follow-up) with postoperative (salvage or adjuvant)
radiotherapy to the prostate bed region (for in- and ex-
clusion criteria see Additional file 1: Figure S1). In short,
patients with locally advanced, node-negative (T3–4/N0)
cancers were eligible in the post-prostatectomy setting
irrespective of laparoscopic/robotic or open surgery or
extent of lymph node resection. Patients with localized
tumors (T1–2/N0) were not included in the main model
as only 8 out of 52 patients had received WPRT (15.4%);
whereas almost all patients with node-positive disease
had received WPRT (38 out of 40; 95%); therefore,
pooled analyses including those two groups were
deemed exploratory and are reported in the supplemen-
tary appendix.
Radiotherapy
The clinical target volume-1 (CTV-1) included prostate
bed, bladder neck, and urethral anastomosis regions in
accordance with the Princess Margaret Hospital guide-
lines [21]. The seminal vesicle bed was always included
in CTV-1 [22]. CTV-2 included prostate bed, bladder
neck and anastomosis but not necessarily the seminal
vesicle bed; both CTVs included localizable disease. Out
of CTV-1/2, PTV-1/2 were created using a margin of 3–
8 mm. PTV-1 and PTV-2 were always irradiated with 60
Gy in 30 fractions. Patients without localizable tumors
then received an additional dose of 6–7 Gy to PTV-1
plus 10 Gy as a 4-fraction simultaneous integrated boost
(SIB) to PTV-2. Patients with detectable tumor manifes-
tations (positive imaging or positive margins) received a
5-fraction SIB of 11–12 Gy to PTV-1 and 15 Gy to PTV-
2. Assuming an α/β of 1.5, this would result in an EQD-
2 to PTV-1 of 73.37 or 66.5 Gy and PTV-2 doses of
79.29 Gy (“high-dose cohort”) or 71.43 Gy (“lower-dose
cohort”) for patients with detectable and undetectable
disease, respectively.
SIB fractions were always applied as IMRT (or Volu-
metric Modulated Arc Therapy, VMAT) using daily
image-guidance (IGRT) with cone-beam computed tom-
ography (CBCT). The initial 60 Gy were either given as
a 3D-conformal or as an IMRT/VMAT-based approach.
Elective nodal irradiation with 44 Gy in 22 fractions
was offered to patients with increased risk of nodal in-
volvement. The latter was determined using surgically
removed nodes: In case of N0 with ≥10 negative
nodes, pelvic radiation was not recommended. In case
of < 10 evaluable nodes and a Roach score [23] of
≥15 (before 2012) or ≥ 25 after adjustment in 2012,
elective pelvic radiotherapy was offered to patients.
For elderly patients (≥70 years) WPRT was offered in
case geriatric assessment yielded a favorable profile;
otherwise, PBRT was recommended using high- or
lower-dose approaches as described. Due to the lack
of definitive evidence, we always accepted the patient’s
decision in favor or against pelvic radiotherapy after
careful discussion of the evidence.
Pelvic target volumes were defined similar to the RTOG
recommendations [20]; briefly, the superior border was the
L5/S1 interspace (in case of positive nodes: L4/L5), the
pubic symphysis was the anterior, and the lower aspect of
the obturator foramen the inferior border. Dose constraints
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were in line with QUANTEC [24] recommendations for
bladder, rectal, and bowel doses.
Concurrent ADT was used on an individual basis in
our department prior to the publication of the GETUG-
AFU-16 [5] trial and the RTOG-9601 [6] study. After
publication of the results, we discussed the possibility of
concurrent ADT with all patients who had postoperative
radiotherapy; for this analysis, patients who had received
concurrent ADT were not excluded.
Statistical calculations
All analyses were performed using SPSS (V15.0), or “R”,
a language and environment for statistical computing.
Survival curves were computed using the Kaplan-Meier
approach; log-rank tests were used to calculate univari-
ate associations with survival. Univariately associated
variables entered a multivariate stepwise Cox regression
model to identify independent predictors.
To address (unrelated) death as a confounder, bPFS
analyses were complemented by freedom from biochem-
ical failure (FFBF) analyses in which death events were
censored. This was done to account for the increased




Baseline characteristics and differences between WPRT
(n = 43), and PBRT (n = 77) patients are shown in
Table 1. The median follow-up time was 62.2 months
(range: 8.5–106.5 months). In the whole cohort of 120
locally advanced patients, average bPFS was 54.6 (95%-
CI 46.3–62.9; median: 46.9) months and FFBF was 56.2
(47.8–64.6; median: 51.4) months.
Radiotherapy factors univariately associated with bPFS or
FFBF
WPRT was significantly associated with bPFS (p = 0.032)
and FFBF (p = 0.033) in univariate analysis (see Fig. 1a-b
and Table 1 for details on baseline imbalances).
Dose escalation (79.29 vs. 71.43 Gy EQD-2) was per-
formed in patients with identifiable tumors, defined as
positive margins with known localization or detectable via
MRI or PET-CT; therefore, 93.6% of high-dose patients
had positive margins compared to 4.8% in the lower-dose
cohort and, vice versa, 97.3% of margin-positive patients
had received high doses. Furthermore, 95.2% of patients
with lower-dose radiotherapy had salvage treatment com-
pared to 23.1% of patients with high-dose radiotherapy
(p < 0.001). Due to these imbalances, it is impossible to
distinguish benefits associated with dose escalation (p <
0.001 for bPFS and FFBF; Fig. 2a-b) from benefits associ-
ated with positive margins [25] or benefits from a negative
risk selection in salvage patients (patients in the
postoperative setting may not progress despite risk factors,
even without treatment [1–3]); accordingly, salvage vs.
postoperative radiotherapy was associated with shorter
bPFS and FFBF (both p < 0.001; Additional file 2: Figure
S2a-b). We observed a trend for an improved bPFS (p =
0.055) and significantly improved FFBF (p = 0.037) in pa-
tients with shorter S-RT-Intervals (< 4months).
Only 13 patients (11%) had received ADT which was
associated with a numerical but not significant benefit in
bPFS (Additional file 3: Figure S3a-b). Duration of con-
current ADT-usage was heterogeneous in our patient
cohort with 6 patients receiving 6 months, which was
the minimum duration, a median of 12 months and a
maximum of 57.6 months.
Other factors univariately associated with bPFS or FFBF
Post-surgery, pre-radiotherapy PSA values of ≥0.2 ng/ml
were associated with decreased bPFS and FFBF (p =
0.022 and p = 0.012; Additional file 4: Figure S4a-b; a
higher PSA cut-off of 0.5 ng/ml was also associated with
bPFS and FFBF: p = 0.049 and p = 0.022). Elderly pa-
tients (≥70 years) did not have a significantly different
bPFS (p = 0.101) but a trend towards shorter FFBF (p =
0.066). Initial, i.e. preoperative PSA values (< 10, 10–20,
≥20 ng/ml) were not associated with bPFS or FFBF after
radiotherapy (p > 0.1 for all comparisons). Gleason
scores of surgical specimens were significantly associated
with bPFS (p = 0.003) and FFBF (p = 0.008; Gleason 8–
10 vs. Gleason 6–7; Additional file 4: Figure S4c-d).
Roach scores at a cut-off of 15 were not associated with
bPFS or FFBF; however, only 21 patients (17.5%) in this
advanced patient cohort had Roach scores of < 15. For
Roach scores ≥25, there was a significantly decreased
bPFS but only a trend for worse FFBF (p = 0.043 and
p = 0.085, respectively; Additional file 4: Figure S4e-f ).
Multivariate models
Multivariate Cox models are shown in Table 2 and Table
3; based on available evidence [5, 6, 19], we decided to
enter concurrent ADT-usage into the models despite the
insignificant findings in the univariate model which may
have been caused by the low number of patients in the
ADT-usage group (n = 13). Higher Gleason scores were
independently associated with shorter and WPRT was
independently associated with longer bPFS and FFBF, re-
spectively. High-dose radiotherapy (used in patients with
positive margins or detectable disease) showed a trend
towards longer bPFS and FFBF (p = 0.064 and p = 0.073)
. Significant predictors in Table 2 and Table 3 remained
significant when ADT-usage was excluded as a variable
and/or Roach scores (cut-off 25) were used instead of or
in addition to Gleason scores.
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Table 1 Baseline characteristics of 120 patients with locally advanced tumors who received fossa-only (n = 77) or elective pelvic
nodal irradiation (WPRT; n = 43)
Baseline Characteristics Fossa-only (n = 77) WPRT (n = 43) Difference
Age at radiation therapy in years
Mean 66.9 66.9 p = 0.98
Standard deviation 7.5 6.5
Initial PSA value in ng/ml
Mean 18.1 18.6 p = 0.927
Standard deviation 26.8 18.0
Gleason score (surgical specimens, No., percentage)
Gleason 6 2 (2.6%) 0
Gleason 7a 15 (19.5%) 9 (20.9%)
Gleason 7b 30 (39.0%) 10 (23.3%) p = 0.087§
Gleason 8 7 (9.1%) 4 (9.3%)
Gleason 9 22 (28.6%) 19 (44.2%)
Gleason 10 1 (1.3%) 1 (2.3%)
Surgical margin (No., percentage)
R0 29 (37.7%) 16 (37.2%) p = 1.0
R1 48 (62.3%) 27 (62.8%)
R2 – –
Dose level (Gy, prescribed dose, EQD-2 to PTV-2)
Lower-dose (71.43 Gy) 29 (37.7%) 13 (30.2%) p = 0.433
High-dose (79.29 Gy) 48 (62.3%) 30 (69.8%)
Time from surgery to radiation therapy (S-RT-Interval in months)
Mean 13.3 6.1 p = 0.003#
Median 5.1 3.6
Standard deviation 18.7 6.2
Salvage or postoperative (adjuvant or R1) treatment indication (No., percentage)
Salvage 41 (53.2%) 17 (39.5%) p = 0.184
Postoperative 36 (46.8%) 26 (60.5%)
Roach scores
Mean 28.9 32.8 p = 0.27
Standard deviation 20.8 15.0
Concurrent androgen deprivation therapy (ADT)
Yes 7 (9.1%) 6 (14%) p = 0.541
No 70 (90.9%) 37 (86%)
Pathologically identified number of lymph nodes (all N0)
Mean 11.0 5.9 p < 0.001†
Standard deviation 6.5 3.9
≥ 10 nodes identified 42 (54.5%) 2 (4.7%)
< 10 nodes identified 35 (45.5%) 41 (95.3%)
Post-surgery PSA at start of radiotherapy (if available) in ng/ml
Mean 0.73 0.71 p = 0.958
Standard deviation 1.62 1.66
Laparoscopic or retropubic surgery
Laparoscopic 31 (40.3%) 23 (53.5%) p = 0.184
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Salvage and postoperative subgroups with or without
detectable disease
To analyze if the association of WPRT with FFBF and
bPFS observed in the whole cohort was present in both
the salvage and postoperative (including adjuvant) set-
ting, we performed subgroup analyses: WPRT was sig-
nificantly associated with FFBF and bPFS in the salvage
setting (p = 0.029 for bPFS and p = 0.039 for FFBF; Add-
itional file 5: Figure S5a-b) but there was no difference
when radiotherapy was applied postoperatively without
confirmed rise in PSA (p = 0.616 for bPFS and p = 0.56
for FFBF; Additional file 5: Figure S5c-d). However, this
analysis is confounded by our treatment approach: Most
patients (96.8%) treated postoperatively had positive
margins and patients with positive margins had dose es-
calation in almost all cases (97.3%); vice versa, patients
treated in the salvage setting had mostly negative mar-
gins (74.1%) and the lower-dose approach (69%) for un-
detectable disease and negative margins. Therefore, we
cannot specify if WPRT was associated with FFBF and
bPFS in this subgroup because of the salvage situation,
mostly undetectable tumor localizations, lower doses to
the prostate bed or because of a combination of these
factors. Because of the lower numbers in the subgroups
and the significant overlap of variables, a multivariate
model was not applicable in the subgroups.
Toxicity
Grade ≥ 2 toxicity occurred in 20 patients (16.7%) with
an increased risk in patients who received WPRT com-
pared to PBRT (p = 0.005) and in patients who had
79.29 Gy compared to 71.43 Gy to the prostatic bed (p =
0.043). Patients who received low-dose radiotherapy
without pelvic irradiation had the lowest grade 2+ tox-
icity risk (3.4%) followed by high-dose PBRT (12.5%),
low-dose WPRT (15.4%) and high-dose WPRT (36.7%).
There was no grade 3 gastrointestinal toxicity and there
were 10 cases of grade 3 genitourinary toxicity, five after
WPRT/PBRT (11.6%) and five after PBRT-only (6.5%);
all patients with grade 3 events had received 79.29 Gy;
incontinence at baseline which worsened after irradi-
ation counted as an event.
Supplementary analysis including patients with localized
or node-positive disease
All details for the pooled patient cohort of node-negative
patients which included patients with localized disease
(49/52 high-risk, 3/52 intermediate risk) and the full co-
hort, including patients with node-positive disease (n = 40;
all M0) is shown in Additional file 7: Table S1 and
Additional file 6: Figure S6. Briefly, WPRT was associated
with better bPFS and FFBF in the pooled cohorts as well
but it is unknown if results can be extrapolated to any sub-
group other than locally advanced node-negative patients.
Discussion
With this study, we provide a retrospective analysis on the
addition of WPRT to dose-escalated PBRT after prostatec-
tomy for locally advanced node-negative tumors. Most
available studies reported on patients treated with prostate
bed doses ranging from 61.2–72 Gy [19, 26–30] with only
two European series reporting on toxicity of higher-dose
series (EQD-2: 75–77Gy) [15, 31]. WPRT doses in recent
studies ranged from 40 to 54 Gy. WPRT was associated
with a bPFS benefit in some studies [26, 29, 30] while
others described an association limited to subgroups [28]
or found no association at all [27, 32]. The strongest but
not yet fully published evidence so far in support of com-
bining PBRT and WPRT comes from an interim analysis
of the RTOG-0534/SPPORT trial which showed signifi-
cantly different 5-year failure-free survival rates between
PBRT, PBRT plus ADT and WPRT plus ADT arms of
71.7, 82.7 and 89.1%, respectively. Additionally, a trend to-
wards increased metastases-free survival was reported
when WPRT plus ADT was compared to the PBRT arm
without ADT (p = 0.014; the 3-arm trial requires a P value
of 0.0125 for one-sided significance [19]). The trial proto-
col allowed for doses between 64.8–70.2 Gy and (dose-)
subgroup analyses have not yet been reported. Biochem-
ical failure rates were calculated using the Phoenix defin-
ition (PSA 2 ng/ml above nadir or clinical progression);
patients who initiated second salvage prior to this defin-
ition were censored. In our analysis, we used a definition
of two PSA rises and counted patients who initiated sec-
ond salvage as events, even if salvage was initiated after
one increase in PSA levels. Our dose escalation strategy
Table 1 Baseline characteristics of 120 patients with locally advanced tumors who received fossa-only (n = 77) or elective pelvic
nodal irradiation (WPRT; n = 43) (Continued)
Baseline Characteristics Fossa-only (n = 77) WPRT (n = 43) Difference
Retropubic 46 (59.7%) 20 (46.5%)
§Fisher’s exact test, 2-sided for Gleason scores dichotomized at 7 (6–7 vs. 8–10); one-sided testing results in p = 0.056 for an increased Gleason score in the
WPRT group
#The baseline imbalance was significant using the independent samples T-test; imbalance was mainly due to outliers (non-parametric testing did not show a
significant difference: p = 0.07 for Mann-Whitney U-Test
†WPRT was not routinely recommended in patients with ≥10 lymph nodes resected and only performed in two cases after careful discussion with patients. If no
lymph node dissection was performed, the number was scored as zero
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does not allow for a quantification of the benefit associ-
ated with 79.29 Gy EQD-2 compared to 71.43 Gy EQD-2
because we cannot separate benefits associated with posi-
tive margins [25] from benefits of dose escalation which
was almost exclusively used in margin-positive patients
plus a minority (6.4%) who received escalation after detec-
tion of recurrence in imaging (MRI as published [33] or
PET-CT). Additionally, patients who received the higher
a
b
Fig. 1) Biochemical progression-free survival (bPFS; 1a) and freedom from biochemical failure (FFBF; 1b) after whole-pelvic radiotherapy (WPRT)
compared to fossa-only radiotherapy (PBRT) in patients with locally advanced node-negative prostate carcinomas after prostatectomy. Albeit not
significantly different, the PBRT group included a higher percentage of patients with salvage indication (53.2%) compared to the WPRT group
(39.5%); furthermore, patients were treated earlier after surgery in the WPRT group (6.1 months vs. 13.3 months, p = 0.003) likely confounding
these results in favor of WPRT. Other baseline imbalances are shown in Table 1. a Mean bPFS in the WPRT group was 66.4 months (95%-CI: 53.6–
79.2 months; median: 67.6 months) and significantly longer (p = 0.032) compared to 44.7 months (95%-CI: 35.4–54.0 months; median: 28.7 months)
in the PBRT group. b Mean FFBF in the WPRT group was 67.9 months (95%-CI: 55.1–80.7 months; median: 67.6 months) and significantly increased
(p = 0.033) compared to 46.1 months (95%-CI: 36.7–55.5 months; median: 31.5 months) in the PBRT group
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ab
Fig. 2) Biochemical progression-free survival (bPFS; 2a) and freedom from biochemical failure (FFBF; 2b) after high-dose radiotherapy (79.29 Gy)
compared to lower-dose irradiation (71.43 Gy) in patients with locally advanced node-negative prostate carcinomas after prostatectomy who
received PBRT-only or WPRT/PBRT. 93.6% of high-dose patients had positive margins and 97.3% of margin-positive patients had high-dose
irradiation. Furthermore, 95.2% of patients with lower-dose radiotherapy had salvage treatment compared to 23.1% of patients with high-dose
radiotherapy (p < 0.001). Therefore, the benefit in bPFS and FFBF cannot be assigned to either positive margins, higher doses or treatment
indication as it is highly likely that all factors independently contributed to the better outcomes. A multivariate model could not be applied due
to the high overlap of high-dose patients with positive margins. a Mean bPFS in the high-dose (mostly R1/postoperative) group was 64.4 months
(95%-CI: 54.3–74.5 months; median: 75.7 months) and significantly longer (p < 0.001) compared to 32.2 months (95%-CI: 22.3–42.0 months; median:
21.4 months) in the low-dose (R0/salvage) group. b Mean FFBF in the high-dose (R1/postoperative) group was 66.1 months (95%-CI: 56.0–76.2
months; median: 75.7 months) and significantly longer (p < 0.001) compared to 33.4 months (95%-CI: 23.3–43.5 months; median: 21.4 months) in
the low-dose (mostly R0/salvage) group
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dose were mostly treated postoperatively (76.9%) while
95.2% of patients with lower-dose treatment had a salvage
strategy associated with a more unfavorable risk selection.
Therefore, we did not attempt to quantify benefits of the
two dose escalation levels but only analyzed benefits of
WPRT in combination with PBRT at the high-dose-end of
the currently used spectrum, the use of which was more
evenly distributed across subgroups with fewer baseline
imbalances as detailed in Table 1.
We found a 5-year bPFS benefit of 12.1% (FFBF: 11.6%)
after WPRT/PBRT compared to PBRT-only which is higher
compared to the 6.4% benefit observed in the RTOG-0534
dataset after WPRTand ADT vs. PBRT and ADT.
However, due to baseline imbalances and the retrospect-
ive nature of our analysis, the univariate model has to be
interpreted with caution. Nevertheless, multivariate
models showed a significant association of WPRT with
longer bPFS and FFBF and thus, for the analyzed cohort,
confirms the preliminary results of RTOG-0534. This was
also true for the pooled patient cohort which includes pa-
tients who did not have advanced disease and the full co-
hort which also included node-positive patients (T1–4/
N0–1; all M0); however, as mentioned it is uncertain if the
associations of WPRT with outcomes can be extrapolated
to any subgroup other than locally advanced, node-
negative patients in our cohort because almost all patients
with positive nodes were treated with WPRT while only 8
patients with T1–2/N0 tumors had WPRT.
Interestingly, the association of WPRT with longer
bPFS in our cohort was consistent in the subgroup of
patients who had salvage radiotherapy but not in pa-
tients with postoperative/adjuvant strategy. We cannot
determine if the benefit of WPRT occurred because of a
worse risk selection due to the salvage situation, the
negative margin situation or the lower dose approach, as
these factors overlapped. Likely, patients with negative
margins, negative imaging and rising PSA values will
have a higher risk of (undetected) microscopic disease in
the lymph nodes compared to patients with an identifi-
able lesion (including R1) which explains rising or stable
PSA values. Based on our dataset, the benefit of larger
fields may be smaller in patients with positive margins.
This hypothesis is in line with the previously reported
improved outcomes for patients with positive margins in
the adjuvant settings using PBRT [34, 35] and in the
nomogram published by Tendulkar et al. for the salvage
[25] situation (83% of patients had PBRT). In patients
with rising PSA values and an identifiable lesion, the risk
of an occult (second) lesion may be lower compared to
the risk in patients without any identified lesion explain-
ing rising PSA values. However, this hypothesis cannot
be ascertained with our dataset and we look forward to
Table 2 Multivariate survival model for biochemical progression-free survival (bPFS)
Variable Hazard Ratio 95% CI P
Elective pelvic radiotherapy (WPRT) 0.484 0.270–0.870 0.015
Detectable tumor and high-dose radiotherapy 0.517 0.257–1.038 0.064
Salvage radiotherapyc 1.444 0.704–2.962 0.316
Androgen-deprivation therapy (ADT-) usagea 0.764 0.310–1.881 0.558
PSA values at start of radiotherapy above 0.2 ng/ml 1.503 0.850–2.658 0.161
Higher Gleason score of surgical specimensb 1.491 1.128–1.973 0.005
aExcluding ADT-usage as a variable in a sensitivity model did not change results (i.e. WPRT and Gleason remained significant predictors)
bUsing the Roach score (cut-off of ≥25) instead of Gleason scores did not change the overall model and did not influence WPRT as a significant predictor
cInclusion of the S-RT-Interval which was not significant in the bPFS univariate model but in the FFBF analysis did not change the overall model and did not
influence WPRT as a significant predictor
Table 3 Multivariate survival model for freedom from biochemical failure (FFBF); death unrelated to prostate carcinoma was
censored and not counted as an event
Variable Hazard Ratio 95% CI P
Elective pelvic radiotherapy (WPRT) 0.493 0.270–0.898 0.021
Detectable tumor and high-dose radiotherapy 0.525 0.259–1.063 0.073
Salvage radiotherapyc 1.547 0.745–3.215 0.242
Androgen-deprivation therapy (ADT-) usagea 0.673 0.254–1.786 0.427
PSA values at start of radiotherapy above 0.2 ng/ml 1.631 0.904–2.943 0.104
Higher Gleason score of surgical specimensb 1.441 1.080–1.922 0.013
aExcluding ADT-usage as a variable in a sensitivity model did not change results (i.e. WPRT and Gleason remained significant predictors)
bUsing the Roach score (cut-off of ≥25) instead of Gleason scores did not change the overall model and did not influence WPRT as a significant predictor
cInclusion of the S-RT-Interval which was not significant in the bPFS univariate model but in the FFBF analysis did not change the overall model and did not
influence WPRT as a significant predictor
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subgroup analysis of the RTOG-0534 trial which allowed
for patients with positive or negative margins.
WPRT and dose escalation in our dataset were associ-
ated with a significantly increased risk of toxicity; further-
more, pelvic radiotherapy increased symptom burden and
decision regret for radiotherapy (details will be reported
separately). A higher risk of side effects has been described
for dose-escalated radiotherapy in this setting even if most
advanced techniques are applied [13–15]; furthermore, an
increased incidence of toxicity following WPRT in line
with our data has been reported previously [15]. For this
reason, improved accuracy in the identification of patients
who benefit from WPRT is mandatory.
Our study has several weaknesses; first, it is a retrospective
analysis and therefore hypothesis-generating; second, it is
uncertain if our data can be extrapolated to patients who re-
ceived radiation doses below 70Gy; third, ADT-usage was
infrequent and duration was heterogeneous. Finally, we did
not perform a patterns-of-recurrence analysis and did not
systematically analyze imaging prior to inclusion; therefore,
we do not know how many recurrences occurred in the pel-
vis and we cannot provide details on patients with selective
dose escalation to lymph nodes after advanced imaging as
they were excluded from the dataset. Despite these short-
comings our results indicate that WPRT was associated with
longer bPFS and FFBF in patients with locally advanced
node-negative prostate carcinoma who received radiother-
apy to the prostatic bed after prostatectomy; although the
result was significant in the whole patient group, subgroup
analyses indicated that the benefit was more pronounced in
patients with rising PSA values without detectable disease or
positive margins. Our data together with the final results of
RTOG-0534 will help to further refine patient selection in
the postoperative/salvage setting.
Conclusions
We found a significant benefit in bPFS associated with
WPRT in patients with locally advanced prostate carcin-
oma who underwent dose-escalated radiotherapy at the
prostate bed. Incidence of grade 2+ toxicity was higher in
patients who had received WPRT or higher doses (79.29
Gy compared to 71.43 Gy). In subset analyses, the associ-
ation of WPRT with longer bPFS was only observed in pa-
tients with rising PSA values but not in patients with non-
salvage postoperative radiotherapy for positive margins.
Taken together, our data indicate that there is a benefit of
WPRT vs. PBRT in patients with rising PSA values.
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